Our reports had previously indicated that CysLT1 signaling pathway participated in experimental autoimmune encephalomyelitis (EAE) pathogenesis, blocking CysLT1 signaling pathway with montelukast could effectively ameliorate clinical symptoms of EAE [22]. The gene discussed is CYSLTR1; the disease is experimental autoimmune encephalomyelitis.